Presage Biosciences, Inc. is currently evaluating clinical sites for two separate upcoming Phase I/II clinical trials with our clinical stage CDK inhibitor, voruciclib, in combination with other oral treatments. Participation in both studies is not required.
Clinical Study BCL-1601
A Phase I/II study of voruciclib as a single agent and in combination with venetoclax in patients with relapsed/refractory diffuse large B-cell lymphoma.
Click to download BCL-1601 DLBCL Synopsis
Clinical Study TNB-1701
TNB-1701: A Phase 1/2 study of voruciclib and ixazomib as single agents and in combination in patients with advanced solid malignancies and unresectable or metastatic triple negative breast cancer.
Click to download TNB-1601 TNBC Synopsis
If you have questions please contact email@example.com.